Lonza BioResearch Solutions

Are you working with gamma delta T cells? Do you want to achieve clinical-scale expansion? Learn about two distinct activation methods that yield clinical-scale expansion of γδ T cells using our TheraPEAK® T-VIVO® Medium. Discover groundbreaking insights from our expert presentation. This 20-minute session is now available on demand here: https://lnkd.in/gqsVMVrF #celltherapy #tvivo #therapeak

Exciting news: Media developed for gamma delta (γδ) T cells We are thrilled to announce our latest advancement in cell therapy media: TheraPEAK® T-VIVO® Cell Culture Medium now supports the growth and clinical-scale expansion of gamma delta (γδ) T cells. γδ T cells possess a unique capability to infiltrate solid tumors. By optimizing their expansion at clinical scale, we aim to revolutionize solid tumor drug development, paving the way towards a healthier world. Check out our poster for an extensive dataset and protocol insights to achieve clinical-scale expansion of this powerful subset of T cells: https://lnkd.in/eMkUF72s #celltherapy #tvivo #therapeak

We are live at the 28th annual ESACT Conference! Tomorrow we will have two interesting posters pertaining to our TheraPRO® CHO Media System. Please join us from 2:30pm - 4:00pm on 25 June for these poster sessions. Jyoti Rawat, Ph.D, Lead Scientist, R&D will be presenting "TheraPRO® CHO Media System: Streamlining Protein Production for Accelerated Antibody Therapeutics" Ioanna Zormpa, Associate Principal Scientist, R&D will be presenting "TheraPRO® CHO Expansion Media Accelerates Antibody Production with User-Friendly Design for Streamlined Protein Production" #Biosimilars #MonoclonalAntibodies #RecombinantProteins #TheraPRO #PowerCHO #ProCHO

Join us at the 28th Annual ESACT - European Society for Animal Cell Technology Meeting next week in Edinburgh. In addition to our booth, we will also have two posters presented on June 25 from 2:30pm-4:00pm that feature our TheraPRO® CHO media system. For more information please reach out to one of our Lonza team members. #Biosimilars #MonoclonalAntibodies #RecombinantProteins #TheraPRO #PowerCHO #ProCHO

We are happy to share an insightful publication by Dan Cappabianca et al. on a non-viral approach for multiplexed gene-editing in primary human T cells along with non-viral transfection of a CAR construct. Find the full article here: https://lnkd.in/eC23bV3b Reach out to our experts Daniel Komnig, PhD (Europe) or Matthew Hall (US) if you would like to learn more about using #nucleofection for your gene editing approach.

We would like to share the newest publication from Tobias Bexte and colleagues on #nonviral #genomeediting of NK cells. Tobias, being a physician and scientist, uses Sleeping Beauty® transposition from minimalistic DNA vectors to engineer primary NK cells, an efficient approach to generate highly functional CAR NK cells. Find the full paper here: https://lnkd.in/e75aBkjZ #nucleofection #celltherapy

Prime editing is still a relatively young but powerful tool as it allows targeted DNA editing without causing DNA double-strand breaks and it does not require a DNA donor template. Just recently the FDA has even cleared the very first clinical trial using this technology. Find out how scientists are using the Nucleofector® Platform for this novel application area. Download our genome editing publication list which we recently updated to cover latest advancements like prime or base editing. https://lnkd.in/ej4hw_r3 #transfection #nucleofection #genetherapy

Hold onto your lab coats and get ready to dive deep into the forefront of innovation at ISCT this year! Whether you're a seasoned scientist or just a curious mind, this is a presentation you won't want to miss: Gamma delta (γδ) T cells have inherent ability to infiltrate solid tumors but it remains a challenge to generate enough γδ T cells to produce a clinical dose. Addressing this challenge, our expert team led by Dr. Chengkang Zhang has developed two distinct activation methods that yield clinical-scale expansion of γδ T cells using our TheraPEAK® T-VIVO® Medium. The team’s data demonstrates that billions of γδ T cells can be generated using these methods. Interested? Join Dr. CK Zhang for a lunch and learn session at ISCT 2024 in Vancouver on 31st May. Learn more or read the abstract here: https://lnkd.in/e-SDE4Tw #celltherapy #celltherapymanufacturing #therapeak #tvivo #isct2024

Brace yourselves for a presentation that promises to redefine the speed and efficiency of CAR-T manufacturing. Step into the world of rapid innovation with our automated cell manufacturing equipment, the Cocoon® Platform, and discover how it's transforming the landscape of CAR-T manufacturing. The complex process associated with the manufacture of CAR-T cell therapies presents challenges that immensely impact patient accessibility to these treatments. That said, reducing the complexity of the manufacture is key. Hear from Tamara J. Laskowski, PhD how her team has developed an automated workflow that consolidates the critical steps required for transforming T cells into potent CAR-T cell therapies in just 72 hours. Learn more and join us at #ISCT2024 for this insightful presentation: https://lnkd.in/exEtppFW #celltherapy #celltherapymanufacturing #AHealthierWorld #Lonza

Our team is looking forward to meeting you at ISCT2024 in Vancouver. Join us for two insightful lunch presentations or meet us at booth 629. We hope you can stop by!